Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant focal epilepsies treated in the Expanded Access Program

Abstract Objective: Cannabidiol (CBD) treatment was associated with long‐term seizure reduction in patients with various treatment‐resistant epilepsies who participated in the CBD Expanded Access Program. A phase 3 trial showed CBD effectively treats tuberous sclerosis complex (TSC)‐associated seizures, which are primarily of focal origin. However, the effectiveness of CBD in non‐TSC focal epilepsies is not well reported. Here, we evaluate CBD treatment outcomes among patients with a variety of focal epilepsies, including TSC. Methods: Patients received plant‐derived highly purified CBD